Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
GlaxoSmithKline (GB:GSK)
LSE:GSK
Holding GB:GSK?
Track your performance easily
GSK Stock Chart & Stats
Day’s Range0p - 0p
52-Week Range1,371.40p - 1,823.50p
Previous Close1,527.5p
Volume956.47K
Average Volume (3M)7.15M
Market Cap
£62.31B
Enterprise Value74.59B
Total Cash (Recent Filing)£5.18B
Total Debt (Recent Filing)£18.02B
Price to Earnings (P/E)15.4
Beta0.52
Next Earnings
Oct 30, 2024EPS Estimate
£0.47Last Dividend Ex-Date
Aug 15, 2024Dividend Yield3.91%
Share Statistics
EPS (TTM)0.99
Shares Outstanding4,145,061,122
10 Day Avg. Volume8,501,137
30 Day Avg. Volume7,148,498
Standard Deviation0.07
R-Squared0.13
Alpha0.00
Financial Highlights & Ratios
Price to Book (P/B)442.65
Price to Sales (P/S)2.02
Price to Cash Flow (P/CF)15.40
P/FCF Ratio23.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
1,754.33pPrice Target Upside15.09% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
GlaxoSmithKline News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsGSK announced its Nucala COPD PIII trial (MATINEE) has met its primary endpoint, with a clinically meaningful and statistically significant reduction in exacerbations vs placebo in patients with baseline eosinophils >300 cells/uL.
Oncology PerformanceOncology assets Ojjaara and Jemperli performed 50% and 14% above expectations, respectively, driven by strong rollout and new indications.
Product RolloutShingrix confirmed broader European rollout progressing well with France the next big opportunity.
Bears Say
Litigation RiskThe Delaware Supreme Court's acceptance of GSK’s appeal request for the Delaware District court Daubert ruling has led to approximately 73,000 Zantac claims progressing to trial, causing a sharp correction in GSK shares.
Market Share DeclineGSK expects its US market share of RSV to drop to around 66% from 70% as the new RSV season progresses, due to contracting dynamics.
Product Pipeline WeaknessGSK's relatively weak late-stage pipeline raises concerns about its ability to sustain future growth, especially as key franchises like Shingrix and Dolutegravir peak.
---
Options Prices
Currently, No data available
---
Ownership Overview
1.28% Insiders
11.90% Mutual Funds
10.84% Other Institutional Investors
75.99% Public Companies and Individual Investors
GSK FAQ
What was GlaxoSmithKline’s price range in the past 12 months?
GlaxoSmithKline lowest share price was 1371.40p and its highest was 1823.50p in the past 12 months.
What is GlaxoSmithKline’s market cap?
Currently, no data Available
When is GlaxoSmithKline’s upcoming earnings report date?
GlaxoSmithKline’s upcoming earnings report date is Oct 30, 2024 which is in 36 days.
How were GlaxoSmithKline’s earnings last quarter?
GlaxoSmithKline released its earnings results on Jul 31, 2024. The company reported 0.434p earnings per share for the quarter, beating the consensus estimate of 0.382p by 0.052p.
Is GlaxoSmithKline overvalued?
According to Wall Street analysts GlaxoSmithKline’s price is currently Undervalued.
Does GlaxoSmithKline pay dividends?
GlaxoSmithKline pays a Annually dividend of 15p which represents an annual dividend yield of 3.91%. See more information on GlaxoSmithKline dividends here
What is GlaxoSmithKline’s EPS estimate?
GlaxoSmithKline’s EPS estimate is £0.47.
How many shares outstanding does GlaxoSmithKline have?
GlaxoSmithKline has 4,145,061,000 shares outstanding.
What happened to GlaxoSmithKline’s price movement after its last earnings report?
GlaxoSmithKline reported an EPS of 0.434p in its last earnings report, beating expectations of 0.382p. Following the earnings report the stock price went down -1.978%.
Which hedge fund is a major shareholder of GlaxoSmithKline?
Currently, no hedge funds are holding shares in GB:GSK
---
GlaxoSmithKline Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
1,754.33p (15.09% Upside)
1,754.33p (15.09% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
3.80%
12-Months-Change
Fundamentals
Return on Equity
29.80%
Trailing 12-Months
Asset Growth
-2.35%
Trailing 12-Months
Company Description
GlaxoSmithKline
In the pharmaceutical industry, GlaxoSmithKline ranks as one of the largest companies by total sales. The company wields its might across several therapeutic classes, including respiratory, oncology, and antiviral, as well as vaccines and consumer healthcare products. Glaxo uses joint ventures to gain additional scale in certain markets like HIV and consumer products.
---
GSK Stock 12 Month Forecast
Average Price Target
1,754.33p
▲(15.09% Upside)
Technical Analysis
Best Analysts Covering GSK
1 Year
1 Year Success Rate
23/37 ratings generated profit
1 Year Average Return
+5.41%
reiterated a buy rating 6 days ago
Copying Emmanuel Papadakis's trades and holding each position for 1 Year would result in 62.16% of your transactions generating a profit, with an average return of +5.41% per trade.
---